

## BMI CHART

Date: \_\_\_/\_\_\_/\_\_\_

Name: \_\_\_\_\_ Age: \_\_\_\_\_ yrs Sex: M / F

BP: 110/60 Height (cms): 157 cm Weight(kgs): 59.8 kg BMI: \_\_\_\_\_  
*normal*

WEIGHT lbs 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215  
kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 75.0 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97.7

HEIGHT in/cm	Underweight				Healthy				Overweight				Obese				Extremely Obese							
5'0" - 152.4	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
5'1" - 154.9	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	36	37	38	39	40
5'2" - 157.4	18	19	20	21	22	22	23	24	25	26	27	28	29	30	31	32	33	33	34	35	36	37	38	39
5'3" - 160.0	17	18	19	20	21	22	23	24	24	25	26	27	28	29	30	31	32	32	33	34	35	36	37	38
5'4" - 162.5	17	18	18	19	20	21	22	23	24	24	25	26	27	28	29	30	31	31	32	33	34	35	36	37
5'5" - 165.1	16	17	18	19	20	20	21	22	23	24	25	25	26	27	28	29	30	30	31	32	33	34	35	35
5'6" - 167.6	16	17	17	18	19	20	21	21	22	23	24	25	25	26	27	28	29	29	30	31	32	33	34	34
5'7" - 170.1	15	16	17	18	18	19	20	21	22	22	23	24	25	25	26	27	28	29	29	30	31	32	33	33
5'8" - 172.7	15	16	16	17	18	19	19	20	21	22	22	23	24	25	25	26	27	28	28	29	30	31	32	32
5'9" - 176.2	14	15	16	17	17	18	19	20	20	21	22	22	23	24	25	25	26	27	28	28	29	30	31	31
5'10" - 177.8	14	15	15	16	17	18	18	19	20	20	21	22	23	23	24	25	25	26	27	28	28	29	30	30
5'11" - 180.3	14	14	15	16	16	17	18	18	19	20	21	21	22	23	23	24	25	25	26	27	28	28	29	30
6'0" - 182.8	13	14	14	15	16	17	17	18	19	19	20	21	21	22	23	23	24	25	25	26	27	27	28	29
6'1" - 185.4	13	13	14	15	15	16	17	18	18	19	19	20	21	21	22	23	23	24	25	25	26	27	27	28
6'2" - 187.9	12	13	14	14	15	16	16	17	18	18	19	19	20	21	21	22	23	23	24	25	25	26	27	27
6'3" - 190.5	12	13	13	14	15	15	16	16	17	18	18	19	20	20	21	21	22	23	23	24	25	25	26	26
6'4" - 193.0	12	12	13	14	14	15	15	16	17	17	18	18	19	20	20	21	22	22	23	23	24	25	25	26

**Doctors Notes:**

---

---

---

---

---

---

---

---

Signature



UHID	5619183	Date	24/12/2022		
Name	Mrs. Rashmi Dhiman	Sex	Female	Age	33
OPD	PAP				

Zyros / Pils

Drug allergy:  
Sys illness:

LMP: 6.12.22

PMC: 3 ped, RMP

- Pt's last pap smear in 2021
- Pt asked to bring reports at next visit
- Pt's next routine pap smear in 2024.

Adv

- FUC reports
- pap smear zyrosly
- ~~mammography~~
- note
- self breast exam<sup>n</sup> monthly

hha

Hiranandani Healthcare Pvt. Ltd.  
Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703  
Board Line: 022 - 39199222 | Fax: 022 - 39199220 9112  
Emergency: 022 - 39199100 | Ambulance: 1255  
For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300  
www.fortishealthcare.com |  
CIN : U85100MH2005PTC154823  
GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



Hiranandani  
HOSPITAL

UHID	5619183	Date	24/12/2022
Name	Mrs. Rashmi Dhiman	Sex	Female Age 33
OPD	Dental ( Opd Room no- 12)		

Drug allergy:  
Sys illness:

No significant findings

Advised Routine oral prophylaxis

Dr Diksha Kaka.

UHID 5619183 Date 24/12/2022  
 Name Mrs. Rashmi Dhiman Sex Female Age 33  
 OPD Opthal ( Opd Room no- 14)

Drug allergy: → Not known  
 Sys illness: → Cold (wild)

Ch. No

Hc No

U. of V. → R 6/60  
 → L 6/60 (Bh)

R. of V. → R - 4.28 am 6/6  
 → L - 4.28 am - 100 x 10<sup>6</sup> 6/6

N.R. → R No  
 → L No

F.O.P. → R → 14.2.  
 → L → 14.4.

All over

~~Contd~~  
 20-2000  
 2000 / 3000  
 ↓  
 2000 / 3000  
 Contd

Cela V. → Nand J. Cont (BGS)

**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183** CLIENT PATIENT ID : UID:5619183  
 ACCESSION NO : **0022VL005355** AGE : 33 Years SEX : Female ABHA NO :  
 DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46  
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF


**CLINICAL INFORMATION :**  
 UID:5619183 REQNO-1349041  
 CORP-OPD  
 BILLNO-150122OPCR066016  
 BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**KIDNEY PANEL - 1**

**BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN 8 6 - 20 mg/dL  
 METHOD : UREASE - UV



**CREATININE EGFR- EPI**

CREATININE 0.47 Low 0.60 - 1.10 mg/dL  
 METHOD : ALKALINE PICRATE KINETIC JAFFES

AGE 33 years

GLOMERULAR FILTRATION RATE (FEMALE) 128.83 Refer Interpretation Below mL/min/1.73m<sup>2</sup>  
 METHOD : CALCULATED PARAMETER





Cert. No. MC-2275



**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46


CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
CORP-OPD  
BILLNO-150122OPCR066016  
BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------



**BUN/CREAT RATIO** **17.02** High 5.00 - 15.00

BUN/CREAT RATIO  
METHOD : CALCULATED PARAMETER

**URIC ACID, SERUM** 3.7 2.6 - 6.0 mg/dL

URIC ACID  
METHOD : URICASE UV

**TOTAL PROTEIN, SERUM** 7.7 6.4 - 8.2 g/dL

TOTAL PROTEIN  
METHOD : BIURET

**ALBUMIN, SERUM** 3.8 3.4 - 5.0 g/dL

ALBUMIN  
METHOD : BCP DYE BINDING

**GLOBULIN** 3.9 2.0 - 4.1 g/dL

GLOBULIN  
METHOD : CALCULATED PARAMETER

**ELECTROLYTES (NA/K/CL), SERUM** 137 136 - 145 mmol/L

SODIUM, SERUM

POTASSIUM, SERUM 4.32 3.50 - 5.10 mmol/L

SRL Ltd  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222,022-49723322,  
022-39199222,022-49723322



Scan to View Details



Scan to View Report



Patient Ref. No. 2200000817



Cert. No. MC-2275



# LABORATORY REPORT

PATIENT NAME : MRS. RASHMI DHIMAN

CLIENT PATIENT ID : UID:5619183

PATIENT ID : FH.5619183

ACCESSION NO : 0022VL005355

AGE : 33 Years SEX : Female  
RECEIVED : 24/12/2022 09:07:30

ABHA NO :  
REPORTED : 24/12/2022 13:52:46

DRAWN : 24/12/2022 09:07:00

REFERRING DOCTOR : SELF

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

### CLINICAL INFORMATION :

UID:5619183 REQNO-1349041  
CORP-OPD  
BILLNO-150122OPCR066016  
BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval	Units
METHOD : ISE INDIRECT CHLORIDE, SERUM METHOD : ISE INDIRECT		101	98 - 107	mmol/L
<b>Interpretation(s)</b>				
<b>PHYSICAL EXAMINATION, URINE</b>				
COLOR METHOD : PHYSICAL		PALE YELLOW		
APPEARANCE METHOD : VISUAL		SLIGHTLY HAZY		
<b>CHEMICAL EXAMINATION, URINE</b>				
PH METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD		6.0	4.7 - 7.5	
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)		1.010	1.003 - 1.035	
PROTEIN METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		NOT DETECTED	NOT DETECTED	
GLUCOSE METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		NOT DETECTED	NOT DETECTED	
KETONES METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD		NOT DETECTED	NOT DETECTED	
BLOOD METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE		DETECTED (+)	NOT DETECTED	
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN		NOT DETECTED	NOT DETECTED	
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT		NORMAL	NORMAL	
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)		NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE		NOT DETECTED	NOT DETECTED	
<b>MICROSCOPIC EXAMINATION, URINE</b>				
RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION		3 - 5	NOT DETECTED	/HPF
PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION		5-7	0-5	/HPF

SRL Ltd  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222,022-49723322,  
022-25500000



Scan to View Details



Scan to View Report



Patient Ref. No. 22000000



Cert. No. MC-2275



**LABORATORY REPORT**  
**PATIENT NAME : MRS. RASHMI DHIMAN**

CLIENT PATIENT ID : UID:5619183

PATIENT ID : **FH.5619183**

ACCESSION NO : **0022VL005355** AGE : 33 Years SEX : Female ABHA NO :  
DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
CORP-OPD  
BILLNO-150122OPCR066016  
BILLNO-150122OPCR066016

Test Report Status	Results	Biological Reference Interval	Units
EPITHELIAL CELLS	10-15	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
REMARKS	URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.		

**Interpretation(s)**

**Interpretation(s)**  
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)  
Causes of decreased level include Liver disease, SIADH.  
CREATININE EGFR- EPI-  
GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.  
A GFR of 60 or higher is in the normal range.  
A GFR below 60 may mean kidney disease.  
A GFR of 15 or lower may mean kidney failure.  
Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.  
The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation especially in patients with higher GFR. This results in reduced misclassification of CKD.  
The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.  
URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM, Metabolic syndrome  
Causes of decreased levels-Low Zinc intake,OCP, Multiple Sclerosis  
TOTAL PROTEIN, SERUM-Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is made up of albumin and globulin  
Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease  
Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.  
ALBUMIN, SERUM-  
Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

SRL Ltd  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222, 022-49723322,  
022-49723322



Scan to View Details




Scan to View Report



Patient Ref. No. 22000000817





**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
CORP-OPD  
BILLNO-150122OPCR066016  
BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

**HAEMATOLOGY - CBC**

**CBC-5, EDTA WHOLE BLOOD**

**BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN (HB)	<b>11.6</b>	Low	12.0 - 15.0	g/dL
METHOD : SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	4.73		3.8 - 4.8	mil/ $\mu$ L
METHOD : ELECTRICAL IMPEDANCE				
WHITE BLOOD CELL (WBC) COUNT	6.40		4.0 - 10.0	thou/ $\mu$ L
METHOD : DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY				
PLATELET COUNT	252		150 - 410	thou/ $\mu$ L
METHOD : ELECTRICAL IMPEDANCE				

**RBC AND PLATELET INDICES**

HEMATOCRIT (PCV)	<b>35.1</b>	Low	36 - 46	%
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	<b>74.2</b>	Low	83 - 101	fL
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	<b>24.5</b>	Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	33.0		31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER				
RED CELL DISTRIBUTION WIDTH (RDW)	<b>16.7</b>	High	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER				
MENTZER INDEX	15.7			
MEAN PLATELET VOLUME (MPV)	<b>11.3</b>	High	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER				

**WBC DIFFERENTIAL COUNT**

NEUTROPHILS	46		40 - 80	%
METHOD : FLOW CYTOMETRY				
LYMPHOCYTES	35		20 - 40	%
METHOD : FLOW CYTOMETRY				
MONOCYTES	09		2 - 10	%
METHOD : FLOW CYTOMETRY				
EOSINOPHILS	<b>10</b>	High	1 - 6	%
METHOD : FLOW CYTOMETRY				

**SRL Ltd**  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222,022-49723322,  
022-11-2222-100001, 022-11-2222-100002



Scan to View Details



Scan to View Report





Cert. No. MC-2275



LABORATORY REPORT

PATIENT NAME : MRS.RASHMI DHIMAN

PATIENT ID : FH.5619183

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : 0022VL005355 AGE : 33 Years SEX : Female ABHA NO :
DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:5619183 REQNO-1349041
CORP-OPD
BILLNO-150122OPCR066016
BILLNO-150122OPCR066016

Table with 3 columns: Test Report Status, Results, Biological Reference Interval. Rows include BASOPHILS, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT, ABSOLUTE MONOCYTE COUNT, ABSOLUTE EOSINOPHIL COUNT, ABSOLUTE BASOPHIL COUNT, NEUTROPHIL LYMPHOCYTE RATIO (NLR), MORPHOLOGY (RBC, WBC, PLATELETS).

Interpretation(s)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 38 High 0 - 20 mm at 1 hr
METHOD : WESTERGREN METHOD

SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222,022-49723322,



Scan to View Details



Scan to View Report



Patient Ref. No. 2200000081762

PATIENT ID : **FH.5619183** CLIENT PATIENT ID : UID:5619183  
 ACCESSION NO : **0022VL005355** AGE : 33 Years SEX : Female ABHA NO :  
 DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46  
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**  
 UID:5619183 REQNO-1349041  
 CORP-OPD  
 BILLNO-150122OPCR066016  
 BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

**Interpretation(s)**

**ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-**  
 Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

**TEST INTERPRETATION**

**Increase** in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm/hr(95 if anemic). ESR returns to normal 4th week post partum.

**Decreased** in: Polycythemia vera, Sickle cell anemia

**LIMITATIONS**

**False elevated** ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

**False Decreased** : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

**REFERENCE :**

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

**IMMUNOHAEMATOLOGY**

**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP TYPE B  
 METHOD : TUBE AGGLUTINATION  
 RH TYPE POSITIVE  
 METHOD : TUBE AGGLUTINATION

**Interpretation(s)**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

**BIOCHEMISTRY**

**LIVER FUNCTION PROFILE, SERUM**

BILIRUBIN, TOTAL	0.61	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.20	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			

**SRL Ltd**  
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
 SECTOR 10,  
 NAVI MUMBAI, 400703  
 MAHARASHTRA, INDIA  
 Tel : 022-39199222,022-49723322,  
 022-49723322



Scan to View Details



Scan to View Report





Cert. No. MC-2275

**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
CORP-OPD  
BILLNO-150122OPCR066016  
BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
BILIRUBIN, INDIRECT		0.41	0.1 - 1.0 mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN		7.7	6.4 - 8.2 g/dL
METHOD : BIURET			
ALBUMIN		3.8	3.4 - 5.0 g/dL
METHOD : BCP DYE BINDING			
GLOBULIN		3.9	2.0 - 4.1 g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO		1.0	1.0 - 2.1 RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)		19	15 - 37 U/L
METHOD : UV WITH P5P			
ALANINE AMINOTRANSFERASE (ALT/SGPT)		16	< 34.0 U/L
METHOD : UV WITH P5P			
ALKALINE PHOSPHATASE		105	30 - 120 U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)		15	5 - 55 U/L
METHOD : GAMMA GLUTAMYL CARBOXY 4-NITROANILIDE			
LACTATE DEHYDROGENASE		141	100 - 190 U/L
METHOD : LACTATE -PYRUVATE			
<b>GLUCOSE FASTING, FLUORIDE PLASMA</b>			
FBS (FASTING BLOOD SUGAR)		95	74 - 99 mg/dL
METHOD : HEXOKINASE			

**SRL Ltd**  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222, 022-49723322,  
022-49723322



Scan to View Details



Scan to View Report



**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**




PATIENT ID : **FH.5619183** CLIENT PATIENT ID : UID:5619183  
 ACCESSION NO : **0022VL005355** AGE : 33 Years SEX : Female ABHA NO :  
 DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46  
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
 CORP-OPD  
 BILLNO-150122OPCR066016  
 BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



**GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA**  
**WHOLE BLOOD**

HBA1C	5.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HB VARIANT (HPLC)			
ESTIMATED AVERAGE GLUCOSE(EAG)	111.2	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER			



Scan to View Details



Scan to View Report

**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**


UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



**Interpretation(s)**

**LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE**

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels result from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

**GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the



Scan to View Details



Scan to View Report



**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183** CLIENT PATIENT ID : UID:5619183  
 ACCESSION NO : **0022VL005355** AGE : 33 Years SEX : Female ABHA NO :  
 DRAWN : 24/12/2022 09:07:00 RECEIVED : 24/12/2022 09:07:30 REPORTED : 24/12/2022 13:52:46  
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041  
 CORP-OPD  
 BILLNO-150122OPCR066016  
 BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

urine.  
**Increased in**  
 Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.  
**Decreased in**  
 Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.  
**NOTE:**  
 While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.  
 High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.  
 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
  - 2.Diagnosing diabetes.
  - 3.Identifying patients at increased risk for diabetes (prediabetes).
- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
  2. eAG gives an evaluation of blood glucose levels for the last couple of months.
  3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

**HbA1c Estimation can get affected due to :**  
 I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.  
 II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.  
 III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods,falsely increasing results.  
 IV.Interference of hemoglobinopathies in HbA1c estimation is seen in  
 a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.  
 b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)  
 c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

**BIOCHEMISTRY- LIPID**

**LIPID PROFILE, SERUM**

CHOLESTEROL, TOTAL	150	< 200 Desirable 200 - 239 Borderline High >= 240 High	mg/dL
METHOD : ENZYMATIC/COLORIMETRIC,CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	84	< 150 Normal 150 - 199 Borderline High 200 - 499 High >=500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	69	High < 40 Low >=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG			
LDL CHOLESTEROL, DIRECT	78	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >= 190 Very High	mg/dL

**SRL Ltd**  
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
 SECTOR 10,  
 NAVI MUMBAI, 400703  
 MAHARASHTRA, INDIA  
 Tel : 022-39199222,022-49723322,  
 Fax : 022-39199222,022-49723322



**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL	81	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---------------------	----	--	-------

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO	2.2	<b>Low</b> 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
----------------	-----	---	--


METHOD : CALCULATED PARAMETER

LDL/HDL RATIO	1.1	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
---------------	-----	--	--

METHOD : CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN	16.8	</= 30.0	mg/dL
------------------------------	------	----------	-------

METHOD : CALCULATED PARAMETER



Scan to View Details



Scan to View Report





**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**



UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



Scan to View Details



Scan to View Report





Cert. No. MC-2275

LABORATORY REPORT

PATIENT NAME : MRS.RASHMI DHIMAN



PATIENT ID : FH.5619183

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : 0022VL005355

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :


UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



Interpretation(s)

LIPID PROFILE, SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease. This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the "good" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely. HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel : 022-39199222, 022-49723322,



Scan to View Details



Scan to View Report





**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 13:52:46

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult.

**\*\*End Of Report\*\***

Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession

**Dr. Akta Dubey**  
Consultant Pathologist

**Dr. Rekha Nair, MD**  
Microbiologist



Scan to View Details



Scan to View Report

**LABORATORY REPORT**  
**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183** CLIENT PATIENT ID : UID:5619183  
 ACCESSION NO : **0022VL005454** AGE : 33 Years SEX : Female ABHA NO :  
 DRAWN : 24/12/2022 11:57:00 RECEIVED : 24/12/2022 11:58:59 REPORTED : 24/12/2022 13:35:16  
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR :

**CLINICAL INFORMATION :**


UID:5619183 REQNO-1349041  
 CORP-OPD  
 BILLNO-150122OPCR066016  
 BILLNO-150122OPCR066016

Test Report Status	Results	Biological Reference Interval	Units
<b>Final</b>			

**BIOCHEMISTRY**

**GLUCOSE, POST-PRANDIAL, PLASMA**

PPBS(POST PRANDIAL BLOOD SUGAR) 85 70 - 139 mg/dL  
 METHOD : HEXOKINASE



**Comments**

NOTE: - RECHECKED FOR POST PRANDIAL PLASMA GLUCOSE VALUES . TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

**Interpretation(s)**

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

**\*\*End Of Report\*\***

Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession





**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**

PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005454**

AGE : 33 Years SEX : Female

ABHA NO :

DRAWN : 24/12/2022 11:57:00

RECEIVED : 24/12/2022 11:58:59

REPORTED : 24/12/2022 13:35:16

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR :

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Results	Biological Reference Interval	Units
Final			

**Dr.Akta Dubey**  
Consultant Pathologist

**SRL Ltd**  
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,  
SECTOR 10,  
NAVI MUMBAI, 400703  
MAHARASHTRA, INDIA  
Tel : 022-39199222,022-49723322,  
022-49723322



Scan to View Details



Scan to View Report



Patient Ref. No. 220000008



Cert. No. MC-2984

**LABORATORY REPORT**

**PATIENT NAME : MRS.RASHMI DHIMAN**



PATIENT ID : **FH.5619183**

CLIENT PATIENT ID : UID:5619183

ACCESSION NO : **0022VL005355**

AGE : 33 Years

SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:07:00

RECEIVED : 24/12/2022 09:07:30

REPORTED : 24/12/2022 16:14:31

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

**CLINICAL INFORMATION :**

UID:5619183 REQNO-1349041

CORP-OPD

BILLNO-150122OPCR066016

BILLNO-150122OPCR066016

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**SPECIALISED CHEMISTRY - HORMONE**

**THYROID PANEL, SERUM**

T3	128.3	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	ng/dL
----	-------	---	-------

METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

T4	7.74	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
----	------	---	-------

METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

TSH (ULTRASENSITIVE)	1.910	0.270 - 4.200	µIU/mL
----------------------	-------	---------------	--------

METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

**Interpretation(s)**

**\*\*End Of Report\*\***

Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession

*Sirmukaddam*  
786

**Dr. Swapnil Sirmukaddam**  
Consultant Pathologist

**SRL Ltd**  
BHOO MI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR  
4, KHARGHAR  
NAVI MUMBAI, 410210  
MAHARASHTRA, INDIA  
Tel : 9111591115,  
Fax : 9111591116



Scan to View Details



Scan to View Report



5619183  
33 Years

RASHAMI DHILMAN  
Female

14/12/2022 10:00:00 AM

HC

Rate 84 Sinus rhythm.....Normal P axis, V-rate 50-99  
Probable left atrial enlargement.....P >50ms, <-0.10mV V1

*Sinus rhythm*


--AXIS--

P 75  
QRS 65  
T 40

12 Lead; Standard Placement

-- BORDERLINE ECG --

Unconfirmed Diagnosis



Device:

Speed: 25 mm/sec    Limb: 10 mm/mV    Chest: 10.0 mm/mV

F 50~ 0.50-100 Hz W

100B CL

P?



(For Billing/Reports & Discharge Summary only)

DEPARTMENT OF NIC

Date: 24/Dec/2022

Name: Mrs. Rashmi Dhiman

UHID | Episode No : 5619183 | 65325/22/1501

Age | Sex: 33 YEAR(S) | Female

Order No | Order Date: 1501/PN/OP/2212/138907 | 24-Dec-2022

Order Station : FO-OPD

Admitted On | Reporting Date : 24-Dec-2022 11:26:33

Bed Name :

Order Doctor Name : Dr.SELF.

ECHOCARDIOGRAPHY TRANSTHORACIC

**FINDINGS:**

- No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- No left ventricle diastolic dysfunction.
- No left ventricle Hypertrophy. No left ventricle dilatation.
- Structurally normal valves.
- No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- No tricuspid regurgitation. No pulmonary hypertension.
- Intact IAS and IVS.
- No left ventricle clot/vegetation/pericardial effusion.
- Normal right atrium and right ventricle dimensions.
- Normal left atrium and left ventricle dimension.
- Normal right ventricle systolic function. No hepatic congestion.

**M-MODE MEASUREMENTS:**

LA	26	mm
AO Root	24	mm
AO CUSP SEP	16	mm
LVID (s)	24	mm
LVID (d)	41	mm
IVS (d)	08	mm
LVPW (d)	08	mm
RVID (d)	24	mm
RA	30	mm
LVEF	60	%





(For Billing/Reports & Discharge Summary only)

DEPARTMENT OF NIC

Date: 24/Dec/2022

Name: Mrs. Rashmi Dhiman  
Age | Sex: 33 YEAR(S) | Female  
Order Station : FO-OPD  
Bed Name :

UHID | Episode No : 5619183 | 65325/22/1501  
Order No | Order Date: 1501/PN/OP/2212/138907 | 24-Dec-2022  
Admitted On | Reporting Date : 24-Dec-2022 11:26:33  
Order Doctor Name : Dr.SELF .

**DOPPLER STUDY:**

E WAVE VELOCITY: 1.1 m/sec.  
A WAVE VELOCITY:0.6 m/sec  
E/A RATIO:1.7

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
MITRAL VALVE	N			Nil
AORTIC VALVE	10			Nil
TRICUSPID VALVE	N			Nil
PULMONARY VALVE	4.0			Nil

**Final Impression :**

Normal 2 Dimensional and colour doppler echocardiography study.

DR. PRASHANT PAWAR  
DNB(MED), DNB ( CARDIOLOGY)



DEPARTMENT OF RADIOLOGY

Date: 24/Dec/2022

Name: Mrs. Rashmi Dhiman  
Age | Sex: 33 YEAR(S) | Female  
Order Station : FO-OPD  
Bed Name :

UHID | Episode No : 5619183 | 65325/22/1501  
Order No | Order Date: 1501/PN/OP/2212/138907 | 24-Dec-2022  
Admitted On | Reporting Date : 24-Dec-2022 18:43:54  
Order Doctor Name : Dr.SELF .

X-RAY-CHEST- PA

**Findings:**

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

**DR. YOGINI SHAH**  
**DMRD., DNB. (Radiologist)**



DEPARTMENT OF RADIOLOGY

Date: 26/Dec/2022

Name: Mrs. Rashmi Dhiman  
Age | Sex: 33 YEAR(S) | Female  
Order Station : FO-OPD  
Bed Name :

UHID | Episode No : 5619183 | 65325/22/1501  
Order No | Order Date: 1501/PN/OP/2212/138907 | 24-Dec-2022  
Admitted On | Reporting Date : 26-Dec-2022 14:02:33  
Order Doctor Name : Dr.SELF .

US-WHOLE ABDOMEN

**LIVER** is normal in size (12.9 cm) and shows increased echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber (8.6 mm).

**GALL BLADDER** is partially distended.

**SPLEEN** is normal in size (9.8 cm) and echogenicity.

**BOTH KIDNEYS** are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 11.6 x 3.3 cm.

Left kidney measures 10.0 x 4.8 cm.

**PANCREAS:** Head of pancreas appears unremarkable. Rest of the pancreas is obscured.

**URINARY BLADDER** is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

**UTERUS** is normal in size, measuring 9.3 x 4.6 x 5.3 cm.

Endometrium measures 3.4 mm in thickness.

Both ovaries are normal.

Right ovary measures 2.8 x 1.6 cm.

Left ovary measures 2.6 x 1.5 cm.

No evidence of ascites.

**IMPRESSION:**

- Fatty infiltration of liver. Suggest: clinical correlation.

  
DR. YOGESH PATHADE  
(MD Radio-diagnosis)

K